



## ASX Announcement/Press Release | 18 August 2025 **AdAlta Limited (ASX:1AD)**

### **AdAlta to present at TechKnow Invest Conference**

**AdAlta Limited (ASX:1AD)** (“AdAlta” or “the Company”), developer of next generation cell and protein therapeutic products is presenting at TechKnow Invest Roadshow 2025 on 19 August 2025.

In his presentation, AdAlta’s CEO and Managing Director, Dr Tim Oldham will discuss the twin pillars powering AdAlta’s “East to West” cellular immunotherapy strategy:

- The China innovation boom that is disrupting the global biotech ecosystem; and
- The extraordinary power of reprogrammed human immune cells as living drugs to fight cancer.

Melbourne investors may attend the entire TechKnow Invest program, commencing at 09:20 AEST, at no cost. AdAlta’s presentation will be at:

10:45am AEST  
Tuesday, 19 August 2025  
Rydges Melbourne, 186 Exhibition Street

Dr Oldham will be available for discussions with investors throughout the day.

Registration details can be found here: <https://www.techknowinvestroadshow.com.au/>

A copy of the presentation will be lodged with ASX.

To engage in discussion or ask questions about the presentation, visit AdAlta’s InvestorHub here: <https://investorhub.adalta.com.au/link/PZ3g6y>

This ASX announcement has been authorised for release by the CEO of AdAlta Limited (ASX:1AD).

#### **For further information, please contact:**

##### **AdAlta Limited (ASX:1AD)**

Tim Oldham  
CEO & Managing Director  
P: +61 3 9479 5159  
E: [t.oldham@adalta.com.au](mailto:t.oldham@adalta.com.au)

##### **Media & Investor Enquiries**

The Capital Network  
Julia Maguire  
P: +61 2 7257 7338  
E: [julia@thecapitalnetwork.com.au](mailto:julia@thecapitalnetwork.com.au)

#### **About AdAlta**

AdAlta (ASX: 1AD) is a clinical stage biotechnology business addressing the need for effective cellular immunotherapies for the treatment of solid cancers.

Through its ‘East to West’ strategy, the Company is integrating Asia’s prowess in T cell therapy development with the efficiency and quality of Australia’s clinical and manufacturing ecosystem to create a pathway connecting ‘Eastern’ innovation in cellular immunotherapies with ‘Western’ regulated markets and patients.

AdAlta in-licenses products from Asian originators and invests to establish US FDA regulated manufacturing and conduct Phase I clinical studies with potential to position each product for on-licensing to larger biopharmaceutical companies for potential registrational studies and commercialization.

AdAlta implements a disciplined approach to asset selection focused on highly differentiated T cell therapy products supported by clinical data in solid cancers. The company adopts a capital efficient business model delivering a rapid return on investment in each project that is replicable and provides opportunities to scale across multiple products.

Solid tumours account for 90% of cancers yet remain underserved by current cellular immunotherapies. AdAlta aims to dominate this high-growth segment. The cellular immunotherapy market is projected to grow at a compound annual growth rate of 34% to reach US\$20.3 billion by 2028.

AdAlta's first in class fusion protein, AD-214, takes a whole new approach to fibrotic diseases of the lung and kidney, such as the degenerative and fatal Idiopathic Pulmonary Fibrosis. Following demonstration of efficacy in multiple animal models of disease and two successful Phase I clinical studies, AD-214 is available for partnering.

To learn more, please visit: [www.adalta.com.au](http://www.adalta.com.au)

#### **For more information**



Join our [InvestorHub](#)



Follow us on [LinkedIn](#)



Follow us on [X \(formerly Twitter\)](#)